Home › Maagkanker › Pennsylvania › Pittsburgh
Maagkanker klinische studies in Pittsburgh, PA
14 studies voor Maagkanker zoeken deelnemers op locaties in en rond Pittsburgh (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
Distance-Based Exercise to Preserve Function and Prevent Disability
Rekruteren
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
RekruterenFase 2/3
- UPMC Hillman Cancer Center, Pittsburgh
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
RekruterenFase 2
- Research Site, Pittsburgh
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RekruterenFase 1
- University of Pittsburgh Medical Center, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RekruterenFase 1/2
- Allegheny Health Network, Pittsburgh
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
RekruterenFase 1
- UPMC Hillman Cancer Center, Pittsburgh
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
RekruterenFase 3
- Research Site, Pittsburgh
- Research Site, Pittsburgh
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
RekruterenFase 1/2
- University of Pittsburgh Medical Center, Pittsburgh
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
RekruterenFase 1/2
- Research Site, Pittsburgh
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
RekruterenFase 1
- University of Pittsburg Medical Center _UPMC Hillman Cancer Center, Pittsburgh
Lead-212 PSV359 Therapy for Patients With Solid Tumors
RekruterenFase 1/2
- University of Pittsburgh Medical Center, Pittsburgh
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
RekruterenFase 3
- UPMC Hillman Cancer Center, Pittsburgh
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
RekruterenFase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
RekruterenFase 1
- AHN West Penn Hospital, Pittsburgh
Maagkanker studies in andere steden
- Houston, TX42 studies
- Boston, MA32 studies
- New York City, NY31 studies
- Nashville, TN28 studies
- Baldwin Park, CA22 studies
- Los Angeles, CA22 studies
- Arlington, VA20 studies
- Dallas, TX19 studies
- San Antonio, TX19 studies
- St. Louis, MO18 studies
- Grand Rapids, MI18 studies
- Washington, DC16 studies
Andere studies in Pittsburgh
- Niet-kleincellige longkanker48 studies
- Kanker (alle vormen)41 studies
- Borstkanker39 studies
- Colorectale kanker32 studies
- Metastatische kanker31 studies
- Melanoom31 studies
- Eierstokkanker30 studies
- Endometriumkanker23 studies
- Prostaatkanker23 studies
- Longkanker23 studies
- Plaveiselcelcarcinoom van hoofd en hals22 studies
- Beroerte22 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.